Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems

Executive Summary

FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.

You may also be interested in...



Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles

US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.

Voucher Does Not Guarantee A Priority Review, FDA Says

Final guidance on the tropical disease priority review voucher program says FDA will adhere to priority review goals, which allow agency to complete some outside the stated time frame.

Pediatric Rare Disease Voucher Program Faces Expiration

Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel